Drug Profile
Recombinant human endostatin - Jiangsu Wuzhong Pharmaceutical
Alternative Names: DB-108; SulijiaLatest Information Update: 16 Dec 2020
Price :
$50
*
At a glance
- Originator Jiangsu Wuzhong Pharmaceutical Group
- Class Angiostatic proteins; Antineoplastics; Immunotherapies; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors; Gelatinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 10 Dec 2020 Recombinant human endostatin licensed to Denovo Biopharma worldwide (except China)
- 20 Feb 2019 No recent reports of development identified for phase-III for Non-small cell lung cancer (Combination therapy, Metastatic disease) in China (IV)
- 17 Jan 2017 Jiangsu Wuzhong Pharmaceutical completes a phase III trial in Non-small cell lung cancer in China (NCT03117335)